Sign In
Buy PRME
$3.14
-0.0700 (-2.18%)
At Close: Jun 03, 2026
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
10:16am, Tuesday, 03'rd Mar 2026
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.31 per share a year ago.
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
08:00am, Tuesday, 03'rd Mar 2026
-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Ongoing engagement with FDA for PM3
Prime Drink Group Announces Management Change
05:15pm, Friday, 27'th Feb 2026
MONTRÉAL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce the appointment of Germain Turpin as Interim President and Ch
Prime Medicine to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 25'th Feb 2026
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME) Financial Review
01:26am, Tuesday, 24'th Feb 2026
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two bu
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of “Moderate Buy” from Brokerages
04:44am, Monday, 09'th Feb 2026
Shares of Prime Medicine, Inc. (NYSE: PRME - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are covering the firm, MarketBeat.com reports. T
Prime Drink Group Secures Exclusive North American Licenses for Beach Day Every Day
07:00am, Friday, 06'th Feb 2026
MONTREAL, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has secured exclusive licenses from Prime Capital Inve
Contrasting Eloxx Pharmaceuticals (NASDAQ:ELOX) & Prime Medicine (NYSE:PRME)
01:18am, Monday, 26'th Jan 2026
Eloxx Pharmaceuticals (NASDAQ: ELOX - Get Free Report) and Prime Medicine (NYSE: PRME - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two companies
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:16pm, Wednesday, 14'th Jan 2026
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
08:00am, Wednesday, 07'th Jan 2026
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Drink Group Announces First Closing of Private Placement and Grant of Stock Options
07:00pm, Wednesday, 31'st Dec 2025
MONTREAL, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a first closing of its previously announced non-brokered private placement
Prime: Maintaining 'Buy' On Solidified Catalysts For Wilson's Disease And Beyond
01:29pm, Wednesday, 31'st Dec 2025
Prime Medicine is maintained at a "Buy" rating due to advancing in vivo Prime Editing programs for Wilson's Disease [PM577] and AATD [PM647]. PM577 targets Wilson's Disease with a strategic focus on a
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of “Moderate Buy” by Brokerages
03:24am, Sunday, 21'st Dec 2025
Prime Medicine, Inc. (NYSE: PRME - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are presently covering the stock, Marketbeat.com reports.
Prime Drink Group Announces Private Placement
06:38pm, Wednesday, 17'th Dec 2025
MONTREAL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of uni
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
